“Our financial year 2011/12 has started positively. Organic revenue growth reached 13% and with EBIT up by 20% reaching an EBIT margin two percentage points higher than Q1 last year we continue to demonstrate the scalability of our business model. At the same time we have increased our investment in Research & Development which shows our commitment to building a strong future for Chr. Hansen.
In a challenging world economy it is encouraging to see the strength of our growth platform with solid improvements across our regions and divisions. With the strong performance in Q1 we reiterate our outlook for the year," says CEO Lars Frederiksen.
• Revenue EUR 168 million, up 12% compared to Q1 2010/11
• Organic revenue growth of 13%
• EBIT before special items (b.s.i.) EUR 41 million, up 20% compared to Q1 2010/11. EBIT margin before special items 25% compared to 23% in Q1 last year
• The outlook for 2011/12 remains unchanged: Organic growth is expected to be in the range of 7-10% (Excluding effect on sales prices from change in raw material prices for carmine) and EBIT margin b.s.i. is expected to be above 26%
Please see the quarterly report for further details.
Strong full-year performance-03-11-2011 08:10
Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. All solutions are based on strong research and development competencies and significant technology investments. The company enjoys market leadership in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors Division. There are more than 2,300 dedicated employees in over 30 countries.